KR20170061805A - composition with the effect of Atopy skins - Google Patents

Abstract

The present invention relates to a composition for treating atopic dermatitis, which comprises at least one composition selected from the group consisting of Centella asiatica extract, neomycin sulfate, and salicylic acid as an active ingredient. The present invention relates to a composition for treating dermatitis. As a result, it is possible to ameliorate the itching (pruritus) of atopic dermatitis, to sterilize and sterilize the affected part, to promote skin regeneration of the affected part, to inhibit or eliminate the activity of the factor (abnormal expression of proteins) (Pruritus, skin disease) of atopic dermatitis can be effectively improved and treated.

Description

[0001] The present invention relates to a composition for treating atopic dermatitis,

The present invention relates to a composition for treating atopic dermatitis. By providing a composition comprising Centella asiatica Extract, Neomycin Sulfate and salicylic acid as an active ingredient, To a composition for treating atopic dermatitis which improves symptoms of atopic dermatitis.

Atopic dermatitis has become one of the diseases that rapidly develops in Korea as well as in developed countries. It has been reported that about 20% of the population in developed countries suffer from atopic symptoms.

Although the cause of such atopy has not yet been clarified, atopic dermatitis is generally known to be an immune disease caused by the involvement of genetic and environmental factors.

In general, atopic dermatitis is chronically dry, it is prone to leaning, recurring repeatedly, and is easily caused by dermatitis by various stimuli. In many cases, it is exacerbated repeatedly at intervals of 12 weeks. If not managed properly, it progresses to subacute lesions of erythematous rash with exudation, chronic lesions of thickening, such as leather.

In addition, the pathologic (histologic) examination of atopic dermatitis varies depending on the stage of the lesion, but when it becomes chronic, the epidermis thickens and infiltration of cells involved in various immune responses is observed. In particular, the Langerhans cells responsible for the immune response are increased and have an abnormally increased antigen presenting ability.

And, since the number of mast cells is increased by atopic dermatitis, it shows degranulation state. Most of the patients with atopic dermatitis have elevated serum IgE, especially those with respiratory atrophy such as allergic rhinitis and asthma show high serum IgE. In 85% of patients with atopic dermatitis, the skin test or radioallergosorbent test (RAST) showed positive results for various food and allergen specific IgE. If serum IgE is increased, allergic diseases such as atopic dermatitis Is likely to be diagnosed.

In addition, as a mechanism and a causative protein that aggravates symptoms such as atopic dermatitis and bronchial asthma, a large amount of protein called Periostin is produced in the skin tissue and blood of patients with atopic dermatitis. Ferritin is produced by allergens (antigens) that enter the body and are secreted from activated immune cells (interleukin 4, 13). It is known that ferritin produced here causes inflammation by binding to another protein, entegreen, on the surface of keratinocytes of the skin. In addition, as periaustine binds Entegreen, a new inflammation-inducing substance is formed and deposited in the skin tissue. Even if the antigen is eliminated by the deposited inflammation-inducing substance, a vicious cycle occurs in which the immune cells become more stimulated and the itchy symptoms deepen do.

Recently, there have been a lot of studies on allergic diseases such as those mentioned above. However, even though there have been many advances in the identification and treatment of allergic diseases due to the development of radical immunology, There is no development of treatable drugs. There are no medicines that can cure any of the drugs developed so far, and they are expected to improve symptoms, but the side effects are great.

The treatment of these atopic dermatitis includes the analysis of local exacerbation factors and removal of local steroids and topical calcineurin inhibitors. Antihistamines, skin infection modifiers, and light therapy are the adjunctive therapies. Cyclosporin mofetil And biological therapeutic agents such as Omalizumab and Efalizumab, and therapeutic agents using natural extracts.

However, topical steroids induce skin atrophy in the thin skin of elderly or pediatric patients, cause steroid acne in the face and chest, inhibit the pituitary adrenal gland and cause coughing syndrome, osteoporosis, ovarian necrosis, Side effects such as decrease of functional immune response and growth disorder may occur.

In addition, immunosuppressants have side effects such as elevated blood pressure, increased uric acid, hypertension, headache, and the like. Biological agents have been reported to cause adverse skin conditions, staphylococcal infection, and Hermes infection. In addition, in the case of a therapeutic agent using a natural extract, the therapeutic effect is insignificant.

Accordingly, there is a desperate need for a new atopic dermatitis treating agent having improved therapeutic efficacy, that is, a method for rapidly dissolving itching, sterilizing infected bacteria, and effectively treating atopic dermatitis without adverse effects on normal skin .

Domestic registered patent No. 10-11305500000 Korean Patent No. 10-1307718 Domestic registered patent No. 10-0374047 Korean Patent No. 10-1070805

 Japan Saga University Medical School, Kyushu University. American Journal of Clinical Research (JCI), June 6, 2012

Disclosure of the Invention The present invention has been made to solve the above-mentioned problems, and it is an object of the present invention to provide a medicinal composition containing Centella asiatica extract having excellent skin regeneration activity, neomycin sulfate as a bactericidal antibiotic, salicylic acid having excellent efficacy of removing abnormal proteins causing atopy, The present invention also provides a composition for the treatment of atopic dermatitis, which improves the symptoms of atopic dermatitis by causing a complementary effect to be exhibited by using the combination.

In order to accomplish the above object, the present invention provides a method for treating atopic dermatitis, which comprises an extract of Centella asiatica extract, neomycin sulfate, and salicylic acid as an active ingredient Is a technical feature.

In addition, the composition for treating atopic dermatitis preferably further comprises phenol or dl-camphor.

Herein, 0.1 g to 1.5 g of the Centella asiatica extract, 0.1 g to 0.6 g of the neomycin sulfate, 0.1 g to 0.6 g of salicylic acid is added to 100 ml of the composition for treating atopic dermatitis. acid, 0.01 g to 0.9 g of phenol and 0.01 g to 0.9 g of dl-camphor.

The composition for treating atopic dermatitis may further comprise at least one of Glycolic Acid, Lactic Acid, Papain, Bromelain and Sulfur, .

Here, the composition for treating atopic dermatitis is preferably applied to the skin in the form of an emulsion, an aerosol or a cream.

The present invention provides a composition for treating atopic dermatitis comprising Centella asiatica extract, neomycin sulfate, and salicylic acid as an active ingredient, to provide a composition for treating itch of atopic dermatitis Pruritus), sterilization and sterilization in the affected area, and promotes skin regeneration in the affected area.

Particularly, the use of the centella asiatica extract, which is highly effective for skin regeneration, neomycin sulfate, a bactericidal antibiotic, and salicylic acid, which has an excellent removal effect of an abnormal protein that causes atopy, are used together to produce a complementary effect.

Thus, the present invention has an effect of inhibiting or eliminating the in-vivo activity of factors (abnormal expression of proteins) that cause sterilization and sterilization in the affected area, promote skin regeneration in the affected area, and cause atopic epidemic, It is possible to effectively improve and treat the symptoms of dermatitis (pruritus, skin disease) and to inhibit or eliminate the factors that cause atopic dermatitis, so that it is prevented from recurring and can be effectively used as a new therapeutic agent for atopic dermatitis.

FIG. 1 to FIG. 7 are clinical illustrations showing the case where a therapeutic agent according to one embodiment of the present invention is applied to each part of dogs afflicted with atopic dermatitis.
FIG. 8 is a graph showing a clinical trial in which a therapeutic agent according to an embodiment of the present invention is applied to a neck region of an adult suffering from atopic dermatitis.
FIG. 9 is a graph showing clinical trials of a case where a therapeutic agent according to an embodiment of the present invention is applied to a back region of an adult suffering from atopic dermatitis.
FIG. 10 is a view showing a clinical trial in which a therapeutic agent according to one embodiment of the present invention is applied to a neck region of a male child having atopic dermatitis. FIG.

The present invention relates to a composition for treating atopic dermatitis. By providing a composition comprising Centella asiatica Extract, Neomycin Sulfate and salicylic acid as an active ingredient, Atopic dermatitis, and atopic dermatitis, which ameliorate itching and symptoms of atopic dermatitis.

Particularly, it is possible to express a complementary effect by using Centella asiatica extract having excellent skin regeneration effect, neomycin sulfate as a bactericidal antibiotic, and salicylic acid as an effective protein eliminating protein.

Thus, the present invention has an effect of inhibiting or eliminating the in-vivo activity of factors (abnormal expression of proteins) that cause sterilization and sterilization in the affected area, promotes skin regeneration in the affected area and cause atopic epidemic, (Pruritus, skin disease) of the dermatitis, so as not to recur.

Hereinafter, the present invention will be described in detail.

The present invention includes Centella asiatica Extract, neomycin sulfate, and salicylic acid as active ingredients.

Centella asiatica Extract is a native plant which is called as a maltous rice plant in Korea. The leaves and roots are cleaned and pulverized, and then fermented at room temperature for 3 days. After filtration, Centella asiatica extract .

These centella asiatica extracts contain three active ingredients (Asiaticoside, Asiatic acid, Madecassic acid) and have been used for a long time due to the action of skin elasticity to promote skin regeneration through collagen synthesis.

In addition, it has the effect of stimulating skin regeneration, scarring suppression, wound healing, reducing and restructuring the average diameter of adipocytes, and has the effect of sprouting high quality newborns. The World Health Organization (WHO) (Medicinal plant).

The neomycin sulfate is a bactericidal antibiotic effective for aerobic gram-negative bacilli and staphylococci (a major causative agent of skin infections).

The above-mentioned salicylic acid is a substance that helps corneal erosion and drugs reach deep into the skin. Substances that can replace or additionally use the substance to corrode the skin include the following substances: same.

Any one or a mixture of two or more of Glycolic Acid, Lactic Acid, Papain, Bromelain and Sulfur may be used.

Here, the AHA (Alpha Hydroxy Acid) is Glycolic Acid, Lactic Acid (Lactic Acid), and the BHA (Beta Hydroxy Acid) is Salicylic Acid. , Enzymes (papain, bromelain), and sulfur (sulfur).

In addition, the composition for treating atopic dermatitis preferably further comprises phenol or dl-camphor.

Phenol has a sterilizing effect and an anesthetic effect, and dl-camphor has a stimulating effect by giving local stimulation.

In 100 ml of the composition for treating atopic dermatitis according to the present invention, 0.1 to 1.5 g of the Centella asiatica extract, 0.1 to 0.6 g of the neomycin sulfate, 1 g to 10 g of salicylic acid, 0.01 g to 0.9 g of phenol and 0.01 g to 0.9 g of dl-camphor.

The composition ratio is an optimal composition ratio that maximizes skin regeneration, scar inhibition, wound healing, and sterilization effect, and is excellent in the effect of eliminating abnormal proteins causing atopic dermatitis and keratolytic effect, The effect of skin regeneration is reduced, the effect of sterilization and keratolytic deterioration is lowered, or the effect of each component is not improved even more.

Meanwhile, the composition for treating atopic dermatitis according to the present invention may further comprise herbal extract or albino tree extract.

The herb extract is obtained by grinding a herb such as lavender, thyme, rosemary, lemongrass or chamomile and soaking it in an alcohol solution for one day. The herb extract is obtained by pulverizing a perilla tree and dipping it in an alcohol solution for one day do.

Such herbal extracts or herbal extracts may be added in an amount of 0.1 to 10% by weight based on the total amount of the composition for treating atopic dermatitis to double the pharmacological components of herbs and herbaceous trees, So that the mind and body can be stabilized for the user.

A composition for the treatment of atopic dermatitis of this composition is mixed with an emulsion, an aerosol and a cream base to be applied to the skin and used.

Hereinafter, embodiments of the present invention will be described.

According to one embodiment of the present invention, in 100 ml of the composition for the treatment of total atopic dermatitis, 0.6 g of Centella asiatica extract, 0.2 g of neomycin sulfate, 6 g of salicylic acid, 0.2 g of phenol, 0.3 g of dl- Dye Red No. 40 and emulsion base (distilled water and ethyl alcohol) were used to prepare a therapeutic agent using the composition for treating atopic dermatitis according to the present invention.

The therapeutic agent according to the above-described embodiment was applied to dogs suffering from atopic dermatitis to treat the disease.

FIGS. 1 to 7 show clinical experiments in which a therapeutic agent according to an embodiment of the present invention is applied to each part of dogs afflicted with atopic dermatitis. Clinical experiments were conducted on dogs diagnosed with atopic dermatitis will be.

Two times a day, it was applied to the affected area. After 1 day, symptoms of atopic dermatitis were improved, and after 11 days, it was almost completely cured.

Fig. 3 is a dog head, Fig. 4 is a dog's hips, Fig. 5 is a dog's thigh, Fig. 6 is a dog's tail, Fig. The figure shows the side of a dog's side.

Fig. 1 (a), (b), and (c) are photographs of hairs, After 11 days of treatment, it was confirmed to be cured.

Fig. 2 (a) is a photograph of a part of the abdomen before treatment, Fig. 2 (b) is a photograph after one day, Fig. 2 (c) .

Fig. 3 (a) is a photograph of the head of a dog after 1 day of treatment, Fig. 3 (b) is a photograph of a head part after 4 days, .

Fig. 4 (a) is a photograph of the hips of a dog after 1 day of treatment, and Fig. 4 (b) is a photograph of a hip region of a state after 11 days of treatment.

Fig. 5 (a) is a photograph of a state before the treatment of the leg region, Fig. 5 (b) is a photograph of the state of the leg region before treatment of the leg region, (D) shows the state of the thigh area after 6 days of treatment.

FIG. 6 (a) is a photograph of the state before the treatment of the tail region of the dog, and FIG. 6 (b) is a photograph of the tail region after 11 days after treatment.

FIG. 7 (a) is a photograph of the pre-treatment state of the dog's side, FIG. 7 (b) is a photograph of the pre-treatment state of the flank of the dog, and (c) , And the cured state was confirmed.

FIG. 8 is a photograph showing (a) and (b) after treatment for the neck region of an adult, wherein the therapeutic agent according to the above example was used twice a day in the morning and in the evening, And maintenance effect.

FIG. 9 is a photograph showing (a) and (b) after treatment for the back region of an adult, wherein the therapeutic agent according to the above example was used twice a day in the morning and in the evening, And maintenance effect.

FIG. 10 is a photograph showing (a) and (b) after (a) treatment and (b) treatment of the neck region of a 9-year-old male child. In the case of using the therapeutic agent according to the above- And the symptoms were improved.

Next, the therapeutic agent according to the above example was applied to 10 children (age 9 or younger) with atopic dermatitis. The results are shown in Table 1.

One 2 3 4 5 6 7 8 9 10 Itching ○ △ ○ ○ ○ ○ △ ○ ○ ○ Skin regeneration ○ △ ○ △ ○ ○ △ △ ○ △

(O: very improved, B: slightly improved, X: not much improved)

As shown in Table 1, the therapeutic agent using the composition for treating atopic dermatitis according to the present invention can quickly resolve the itching (pruritus) of atopic dermatitis and can improve the penetration and sterilization effect and sterilize various bacteria residing in the affected part And can be sterilized, and has an effect of promoting skin regeneration of the affected part.

In addition, it has been confirmed that even after the improvement of these symptoms, ingestion of food such as eggs, chocolate, milk, ice cream, etc., which are generally known as atopic diseases, does not recur.

Particularly, the present invention relates to a cosmetic composition comprising a centella asiatica extract having excellent skin regeneration efficacy, neomycin sulfate as a bactericidal antibiotic, salicylic acid having excellent efficacy of removing an abnormal protein causing atopy, will be.

Thus, the present invention has an effect of inhibiting or eliminating the in-vivo activity of factors (abnormal expression of proteins) that cause sterilization and sterilization in the affected area, promote skin regeneration in the affected area, and cause atopic epidemic, It has an advantage that it can be usefully used as a new therapeutic agent for atopic dermatitis since it does not recur while improving and treating symptom of dermatitis (pruritus, skin disease) effectively.

Claims (6)

A composition for treating atopic dermatitis characterized by comprising Centella asiatica extract, neomycin sulfate, and salicylic acid as an active ingredient. The composition for treating atopic dermatitis according to claim 1,
A composition for treating atopic dermatitis characterized by further comprising phenol or dl-camphor. 3. The composition for treating atopic dermatitis according to claim 2,
0.1 to 1.5 g of Centella asiatica extract, 0.1 to 0.6 g of neomycin sulfate, 1 to 10 g of salicylic acid, 0.01 g to 0.9 g of phenol, g, dl-camphor (0.01 g to 0.9 g). The composition for treating atopic dermatitis according to claim 1,
A composition for the treatment of atopic dermatitis, which further comprises one of glyceral acid, glyceral acid, lactic acid, papain, bromelain and sulphur. The composition for atopic dermatitis according to claim 1,
A herb extract or a woody plant extract. ≪ RTI ID = 0.0 > 18. < / RTI > The composition for treating atopic dermatitis according to any one of claims 1 to 5,
Wherein the composition is applied to the skin in the form of an emulsion, an aerosol or a cream.

Images